ALBA THERAPEUTICS CORPORATION CLOSES ON US$30M SERIES A FINANCING

Alba Therapeutics Corporation, an early stage biopharmaceutical company focused on zonulin pathway modulation, today announced the closing of its US$30M Series A financing. SV Life Sciences led the investment round together with Alta Partners and are joined by HealthCap, Red Abbey Venture Partners and the Maryland Venture Fund. Additional participants in the round include existing investors Esperance BioVentures, Astellas Ventures, Maryland TEDCO, and Townsend Capital.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050823005062&newsLang=en)